Nov 3, 2026

Ultragenyx Pharmaceutical Inc. layoff.

AI: Unclear

8-K Item 2.05 filed 2026-11-03: On November 3, 2026, the Company announced a restructuring plan to reduce expenses (the “Restructuring”). As part of the Restructuring, the Company is implementing a workforce reduction of approximately 20% of its employees (the “RIF”). The

Affected

—

Share of workforce

—

Announced

Nov 3, 2026

The count

For the people in it

The day after.

Your rights in this state

The federal WARN Act covers employers with 100 or more full-time workers. It requires 60 days' written notice before a plant closing that affects 50 or more workers at one site, or a mass layoff of 500 or more workers (or 50 to 499 when that is at least a third of the site).

Federal WARN (100+ employees, 60 days' notice) is the only rule we can confirm for this state.

This is an editorial summary, not legal advice.

WARN filed
—
Notice date
—
Separation date
—
Notice given
—

The package, as reported

Severance base
—
Per year of service
—
Benefits continued
—
Equity
—
Outplacement
—

How it was done

Delivery
—
Timing
—
Roles affected
—

If you were in this cohort.

  1. 01

    File for unemployment the week you're separated — not when the severance runs out.

  2. 02

    Check your notice date against the 60-day federal WARN rule.

  3. 03

    Find out whether your COBRA window starts when benefits end or on your separation date.

Read The First 72 Hours →

Pack Finder

No public room for Ultragenyx Pharmaceutical Inc. yet.

A Job Search Council is always open: four to six peers at your career stage, free and volunteer-run.

Evidence

  • SEC filing · Form 8-K · Nov 3, 2026 · SEC accession 0001193125-26-445342

    “On November 3, 2026, the Company announced a restructuring plan to reduce expenses (the “Restructuring”). As part of the Restructuring, the Company is implementing a workforce reduction of approximately 20% of its employees (the “RIF”). The Company estimates that it will incur approximately $25 million in total restructuring and restructuring-related charges, consisting primarily of employee severance payments and other employee-related costs.”
    SEC Form 8-K, Item 2.05 ↗

Sources for this event: sec_8k, SEC Form 8-K, Item 2.05. All Ultragenyx Pharmaceutical Inc. records · Report a correction

Cite this

According to Tracked by PinkSlipped, …

Source: Tracked by PinkSlipped (gotpinkslipped.com/noticed/tracked/event/ultragenyx-pharmaceutical-inc-2026-11-03)

By the PinkSlipped teamUpdated